Venetoclax — Dosing in CKD & Dialysis

Venetoclax (BCL-2 Inhibitor): renal dosing adjustments, dialyzability (Negligible (dialysis unlikely to remove venetoclax significantly, given its large volume of distribution and extensive protein binding)), and renal-relevant safety risk for CKD and dialysis patients. Educational reference for nep

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.